Alembic Pharma receives USFDA approval for Oseltamivir Phosphate

Alembic Pharmaceuticals has received final USFDA approval for Oseltamivir Phosphate capsules, used for treatment of influenza infection. The drug is therapeutically equivalent to the reference listed drug (RLD), Tamiflu Capsules manufactured by Hoffman-La Roche, Inc.

According to market estimates, Oseltamivir Phosphate capsules has an estimated market size of $ 647 million for 12 months ending December 2018. Currently, the company currently has a total of 97 ANDA approvals (85 final approvals and 12 tentative approvals) from USFDA.

Company Profile : Alembic Pharmaceuticals Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.